Literature DB >> 9021965

Demonstration of duck hepatitis B virus in bile duct epithelial cells: implications for pathogenesis and persistent infection.

A J Nicoll1, P W Angus, S T Chou, C A Luscombe, R A Smallwood, S A Locarnini.   

Abstract

Hepatitis B virus (HBV) has been demonstrated in bile duct epithelial cells (BDEC) during chronic infection. The persistence of virus in BDEC may play an important role in disease pathogenesis, and may be at least partly responsible for the relapse phenomenon observed in antiviral treatments using nucleoside analogues. The aims of this study were to examine the morphological changes within the liver in the duck hepatitis B model following bile duct ligation (BDL), and to assess the effect of biliary hyperplasia upon viral DNA and proteins. Seven-day-old ducklings, congenitally infected with the duck hepatitis B virus (DHBV), were subject to BDL. The pathological and virological changes were then followed at 5, 10, 15, and 20 days after ligation. All results were compared with age-matched unligated control birds congenitally infected with DHBV. To assess the early morphological changes, additional animals were sacrificed at 1, 2, 3, and 4 days post-BDL. The proportion of DHBV-infected BDEC, was examined by immunohistochemistry and in situ hybridization. BDL induced rapid biliary hyperplasia, with a doubling time for BDEC of 1.3 days. The proliferated BDEC displayed immunohistochemical features identical to resting BDEC. More than 50% of BDEC in unligated controls, and more than 46% of proliferated BDEC in ligated animals were positive for DHBV DNA and structural proteins. The intensity of immunohistochemical staining and in situ hybridization signal in the BDEC was consistently greater than that of the hepatocytes, both before and after BDL. BDL induces biliary hyperplasia in the duck model, and BDEC division does not reduce the viral burden in infected cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021965     DOI: 10.1002/hep.510250235

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.

Authors:  D Colledge; G Civitico; S Locarnini; T Shaw
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication.

Authors:  William R Addison; Kathie-Anne Walters; Winnie W S Wong; John S Wilson; Danuta Madej; Lawrence D Jewell; D Lorne J Tyrrell
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 3.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

4.  Duck hepatitis B virus replication in primary bile duct epithelial cells.

Authors:  J Y Lee; J G Culvenor; P Angus; R Smallwood; A Nicoll; S Locarnini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors.

Authors:  Vincenzo Cardinale; Rossella Semeraro; Alessia Torrice; Manuela Gatto; Cristina Napoli; Maria Consiglia Bragazzi; Raffaele Gentile; Domenico Alvaro
Journal:  World J Gastrointest Oncol       Date:  2010-11-15

6.  Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.

Authors:  Yan-Ming Zhou; Zheng-Feng Yin; Jia-Mei Yang; Bin Li; Wen-Yu Shao; Feng Xu; Yu-Lan Wang; Dian-Qi Li
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

7.  Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.

Authors:  A J Nicoll; D L Colledge; J J Toole; P W Angus; R A Smallwood; S A Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

8.  Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients.

Authors:  Hai-Ying Lu; Li-Wei Zhuang; Yan-Yan Yu; Hadad Ivan; Chong-Wen Si; Zheng Zeng; Jun Li; Dong-Ming Hou; Xin-Yue Chen; Zhong-Hou Han; Yong Chen
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.